Encouraged by these clinical response data which were generated in breast cancer patients with HER2 amplification/overexpression, we comprehensively assessed the rate of HER2 gene amplification in a large consecutive series of patients with uterine serous papillary and clear cell endometrial cancers. Here, ERBB2 is linked to breast carcinoma.